RBC Capital raised the firm’s price target on Ideaya Biosciences to $36 from $32 and keeps an Outperform rating on the shares. The company’s ESMO presentation and additional top-line data underscore the differentiated profile of darovasertib/”daro” in metastatic uveal melanoma, with responses across HLA-A2 subtypes and continued signs of durability, the analyst tells investors in a research note. The update is reinforcing its thesis on Ideaya path to execution with the clinically derisked lead-asset and multiple shots on goal from additional candidates that are advancing in or into the clinic, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $35 from $32 at JPMorgan
- Ideaya Biosciences announces expansion of darovasertib, crizotinib combination
- Stifel disagrees with negative reaction in Ideaya shares after Amgen data
- Ideaya has positive read from Amgen PRMT5 data, says Oppenheimer
- Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK